GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (FRA:C4X) » Definitions » EBITDA Margin %

Valerio Therapeutics (FRA:C4X) EBITDA Margin % : -387.06% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Valerio Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Valerio Therapeutics's EBITDA for the six months ended in Dec. 2023 was €-6.97 Mil. Valerio Therapeutics's Revenue for the six months ended in Dec. 2023 was €1.80 Mil. Therefore, Valerio Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was -387.06%.


Valerio Therapeutics EBITDA Margin % Historical Data

The historical data trend for Valerio Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics EBITDA Margin % Chart

Valerio Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -224.42 192.85 -110.22 -1,183.85 -1,024.67

Valerio Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.80 - -557.45 - -387.06

Competitive Comparison of Valerio Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Valerio Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valerio Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's EBITDA Margin % falls into.



Valerio Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Valerio Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-18.444/1.8
=-1,024.67 %

Valerio Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-6.967/1.8
=-387.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valerio Therapeutics  (FRA:C4X) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Valerio Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Valerio Therapeutics (FRA:C4X) Business Description

Traded in Other Exchanges
Address
49 Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (FRA:C4X) Headlines

No Headlines